Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482178 | 0.93 | MME (0.43) | MMEPTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL2325576 | 0.82 | MME (0.40) | MMEPTGER4PTGER3PTGER2ALDH1A1 | |
| SCHEMBL8614400 | 0.79 | FAAH (0.47) | SLC6A5FFAR1FFAR4TERTPTPN1 | |
| SCHEMBL8614406 | 0.79 | FAAH (0.47) | SLC6A5FFAR1FFAR4TERTPTPN1 | |
| SCHEMBL9291274 | 0.76 | MME (0.44) | MMEPTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL859388 | 0.73 | MME (0.46) | MMEALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3475153 | 0.72 | ALDH1A1 (0.31) | ALDH1A1MAPTHSD17B10USP2LMNA | |
| SCHEMBL5441570 | 0.70 | HDAC3 (0.32) | MME | |
| SCHEMBL5698002 | 0.70 | ALDH1A1 (0.47) | PTGER4PTGER3PTGER2FFAR1ALDH1A1 | |
| SCHEMBL5697931 | 0.70 | ALDH1A1 (0.47) | PTGER4PTGER3PTGER2FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107041883-B | Application of the specific inhibitor of Hepatitis C Virus accessory receptor CD36 in preparation prevention and treatment infection with hepatitis C virus drug | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-10-29 | — | — | CN | claimed |
| CN-107041883-A | Application of the HCV accessory receptor CD36 specific inhibitor in preventing and treating infection with hepatitis C virus medicine is prepared | 中国医学科学院医药生物技术研究所 | 2017-08-15 | — | — | CN | claimed |
| CN-107041883-B | Application of the specific inhibitor of Hepatitis C Virus accessory receptor CD36 in preparation prevention and treatment infection with hepatitis C virus drug | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-10-29 | — | — | CN | disclosed |
| CN-107041883-A | Application of the HCV accessory receptor CD36 specific inhibitor in preventing and treating infection with hepatitis C virus medicine is prepared | 中国医学科学院医药生物技术研究所 | 2017-08-15 | — | — | CN | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-20150045433-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY | UNIV COLORADO REGENTS (US) | 2015-02-12 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013048591-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY BASED ON FATTY ACID LEVELS IN FASTED VERSUS FED PYTHONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20120142776-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-06-07 | — | — | US | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | MME 297/4885SLC6A5 1526/4885PTGER1 110/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | MME 297/4885SLC6A5 1526/4885PTGER1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.